(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/030663 A1

(51) International Patent Classification[7]: A61K 31/13

(21) International Application Number:
PCT/KR2003/001955

(22) International Filing Date:
25 September 2003 (25.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2002-0060798 5 October 2002 (05.10.2002) KR
10-2003-0053752 4 August 2003 (04.08.2003) KR

(71) Applicant: **HANMI PHARM. CO., LTD.** [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-gun, Kyungki-do 445-910 (KR).

(72) Inventors: **LEE, Jae-Heon**; Sangrok Apt. 611-1201, #1028, Poongdukcheon-ri, Suji-eup, Yongin-si, Kyungki-do 449-846 (KR). **PARK, Gha-Seung**; Hanseong Apt. 103-501, Poongdukcheonri 1-dong, Suji-eup, Yongin-si, Kyungki-do 449-846 (KR). **LEE, Jae-Cheol**; Kyungwonyeonlip Ra-101, #781, Jowon-dong, Jangan-gu, Suwon-si, Kyungki-do 440-849 (KR). **KIM, Han-Kyong**; #180-22, Jeil-ri, Yangji-myeon, Yongin-si, Kyungki-do 449-825 (KR). **CHANG, Young-Kil**; #34-4, Samjeon-dong, Songpa-gu, Seoul 138-180 (KR). **LEE, Gwan-Sun**; Woochang Apt. 3-404, Okeum-dong, Songpa-gu, Seoul 138-739 (KR).

(74) Agent: **JANG, Seong Ku**; 19th Fl., KEC Building, 275-7, Yangjae-dong, Seocho-ku, Seoul 137-130 (KR).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING CRYSTALLINE SIBUTRAMINE METHANESULFONATE HEMIHYDRATE





(I)

(57) Abstract: The present invention relates to a pharmaceutical composition for treating or preventing obesity, comprising novel crystalline sibutramine methanesulfonate hemihydrate of formula (I). The crystalline sibutramine methanesulfonate hemihydrate according to the present invention has a much higher solubility in water, and enhanced stability under a high humidity/temperature condition, as compared with sibutramine hydrochloride monohydrate.

WO 2004/030663 A1